激活转录因子（ATFs）是一类转录因子家族，其通过识别并结合cAMP反应元素结合蛋白（CREB）激活基因表达和转录。ATFs存在于各种病毒中作为细胞基因启动子。ATFs参与调节与各种细胞生理过程相关的哺乳动物基因表达。因此，ATFs在维持细胞内平衡方面发挥着重要作用。ATF2和ATF3主要参与介导压力反应。ATF4调节氧化代谢，与细胞存活相关。ATF5被认为调节凋亡，ATF6参与调节内质网应激（ERS）。ATFs在肿瘤学中受到广泛研究。目前，ATFs治疗神经疾病的研究也越来越多。本文重点关注不同类型的ATFs及其与阿尔茨海默病（AD）的关系。不同ATFs的表达水平在AD患者与健康对照组之间存在显著差异。最近的研究表明，ATFs涉及AD的发病机制，如神经元修复，维持突触活动，维持细胞存活，抑制凋亡和调节压力反应等。本文突出了ATFs在AD治疗中的潜在作用，并系统性地回顾了ATFs在AD研究方面的进展。本文将为AD发病机制和治疗提供基础和创新理解。版权所有 © 2023作者。由Elsevier Masson SAS出版。保留所有权利。

Activating transcription factors, ATFs, is a family of transcription factors that activate gene expression and transcription by recognizing and combining the cAMP response element binding proteins (CREB). It is present in various viruses as a cellular gene promoter. ATFs is involved in regulating the mammalian gene expression that is associated with various cell physiological processes. Therefore, ATFs play an important role in maintaining the intracellular homeostasis. ATF2 and ATF3 is mostly involved in mediating stress responses. ATF4 regulates the oxidative metabolism, which is associated with the survival of cells. ATF5 is presumed to regulate apoptosis, and ATF6 is involved in the regulation of endoplasmic reticulum stress (ERS). ATFs is actively studied in oncology. At present, there has been an increasing amount of research on ATFs for the treatment of neurological diseases. Here, we have focused on the different types of ATFs and their association with Alzheimer's disease (AD). The level of expression of different ATFs have a significant difference in AD patients when compared to healthy control. Recent studies have suggested that ATFs are implicated in the pathogenesis of AD, such as neuronal repair, maintenance of synaptic activity, maintenance of cell survival, inhibition of apoptosis, and regulation of stress responses. In this review, the potential role of ATFs for the treatment of AD has been highlighted. In addition, we have systematically reviewed the progress of research on ATFs in AD. This review will provide a basic and innovative understanding on the pathogenesis and treatment of AD.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.